Page 9 - Pro Solutions News Today

Case Study Oil & Gas Producer TAQA North Chooses InterPros EZMaxMobile To Identify And Correct Hazardous Conditions In The Moment Safety incident reporting increased 100 percent within one month Objectives: Given the extensive, remote locations of their operations, TAQA North required a mobile solution to complement the main Maximo platform upon which the HSSE solution would be built. The mobile solution needed to: Have an offline, disconnected mode, since many of the TAQA N...

Operator Good day and welcome to the Herc Holdings Inc Fourth Quarter 2020 Earnings Conference Call. [Operator instructions] I would now like to turn the conference over to Elizabeth. Please go ahead. Elizabeth Higashi -- Vice President of Investor Relations Thank you, Grant. And thank you all for joining us this morning. Welcome, everyone, to our fourth quarter and full year 2020 earnings conference call. Earlier today, our press release, presentation slides and 10-K were filed with the SEC a...

InterPro Expands Offerings With New Solution for Managing Operations and Maintenance Activities Across Mixed Workforces EZMaxVendor enables organizations to manage tradespeople, contractors and service vendors as an extension of their own workforce News provided by Share this article Share this article BOSTON, Feb. 9, 2021 /PRNewswire/ -- InterPro Solutions, which offers the only suite of mobile solutions designed exclusively for IBM Maximo®, expanded its EZMax Suite today with a new Field Ser...

Dec 11, 2020 10:23am Viatris restructuring efforts could impact up to 20% of its 45,000-strong workforce, putting up to 9,000 jobs on the line. (Pixabay) A little less than a month after Pfizers Upjohn unit and Mylan successfully merged to create generics business Viatris, the company is already looking at ways to slash costs. Newly minted Viatris Friday laid out detailed plans for a global manufacturing initiative that could put thousands of jobs on the line. By 2024 at the latest, the compa...

Dec 11, 2020 9:25am Takeda and COVID-19 vaccines from Chinese firms Sinovac, Clover Biopharma and Sinopharm made our news this week. (Google) Takedas cytomegalovirus candidate, TAK-602, hit its phase 3 goal in transplant patients. The Japanese pharmas Iclusig posted new chronic myeloid leukemia data, touting five-year survival in 60% of patients. China-made COVID-19 vaccines had a busy week: Sinovac plans to double its COVID-19 capacity with a new, $515 million investment from Sino Biopharma; ...